Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: November 2, 2006
Reporting Period: Quarter and nine-month period ended September 30, 2006
This filing serves as a notification that the company announced its financial results for the specified periods. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not included in the body of this Form 8-K.
Material Changes
The filing text does not provide specific details regarding material changes versus prior comparable periods. It only confirms the announcement of results for the quarter and nine months ended September 30, 2006.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on November 2, 2006, which contains the full announcement details.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in this summary text. The document includes standard legal disclaimers regarding the status of the information as "furnished" rather than "filed."
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 2, 2006) for actual revenue, net loss, and cash position figures.
- Verify the specific operational milestones or clinical trial updates mentioned in the press release, as they are not listed in the 8-K body.
- Confirm the company's cash runway and burn rate from the detailed financial statements referenced in the press release.
- Note that the information in this 8-K is not incorporated by reference into other filings unless expressly stated.